ATG36 Antibody

What is ATG36 and what is its primary function in yeast cells?

ATG36 is a protein discovered in Saccharomyces cerevisiae that functions as the primary receptor for pexophagy (selective autophagy of peroxisomes). ATG36 localizes to peroxisomes by interacting with the peroxisomal membrane protein Pex3. The absence of ATG36 specifically blocks pexophagy, while its overexpression can induce pexophagy .

When working with ATG36 antibodies, researchers should be aware that ATG36 expression levels vary under different growth conditions. The protein is upregulated in oleate medium (which promotes peroxisome proliferation) and decreases when cells are switched to starvation medium as pexophagy commences . This dynamic expression pattern makes timing critical when designing immunodetection experiments.

How specific is ATG36 for pexophagy compared to other autophagy pathways?

ATG36 is highly specific for pexophagy. Experimental evidence shows that deletion of the ATG36 gene (atg36Δ) blocks pexophagy but does not affect other selective or non-selective autophagy pathways:

• The Cvt (Cytoplasm-to-vacuole targeting) pathway remains functional in atg36Δ cells, as demonstrated by normal accumulation of Ape1-GFP in the vacuole .

• Mitophagy occurs normally in atg36Δ cells, as shown by the degradation of the mitochondrial marker OM45-GFP after prolonged growth in glycerol medium .

• Non-selective autophagy induced by nitrogen starvation is fully functional in atg36Δ cells, as measured by the uptake of cytosolic alkaline phosphatase into vacuoles .

This high specificity makes ATG36 antibodies valuable tools for investigating the pexophagy pathway without interference from other autophagy mechanisms. When designing experiments with ATG36 antibodies, researchers should include appropriate controls for pexophagy specificity.

What are the key protein interactions that can be studied using ATG36 antibodies?

ATG36 antibodies can be used to investigate several critical protein interactions:

• ATG36-Pex3 interaction: ATG36 is recruited to peroxisomes through its interaction with Pex3, making this a fundamental interaction to study with co-immunoprecipitation approaches .

• ATG36-Atg11 interaction: ATG36 functions as an adaptor by binding Atg11, which links peroxisomes to the pre-autophagosomal structure (PAS) .

• ATG36-Atg8 interaction: Though not containing a canonical AIM (Atg8-interacting motif), ATG36 interacts with Atg8 in vivo, particularly under starvation conditions .

• ATG36-Pex1 interaction: The N-terminal region (first 30 amino acids) of ATG36 interacts with Pex1, part of the peroxisomal exportomer that inhibits ATG36 activation .

When performing co-immunoprecipitation experiments, it's important to note that these interactions are often condition-dependent. For example, the interaction between ATG36 and Atg11/Atg8 is significantly enhanced under starvation conditions compared to oleate growth conditions .

How can ATG36 antibodies be used to study the regulation of pexophagy by phosphorylation?

ATG36 activity is regulated through phosphorylation by the casein kinase Hrr25, and this phosphorylation status can be detected using phospho-specific antibodies or by observing mobility shifts in standard immunoblotting . Research has shown that ATG36 appears as a set of fuzzy bands with differential mobility depending on growth conditions, reflecting its phosphorylation state .

To study ATG36 phosphorylation:

• Use immunoblotting to detect mobility shifts that indicate phosphorylation status

• Compare untreated samples with those treated with CIP (calf intestinal phosphatase) to confirm phosphorylation

• Monitor phosphorylation levels under different conditions, especially comparing rich media versus starvation conditions

• Combine with genetic approaches, such as using hrr25 mutants, to validate the role of specific kinases

Researchers have found that latent activation of ATG36 by Hrr25 in rich media is repressed by the ATPase activity of the Pex1/6 complex . ATG36 antibodies can help monitor this regulatory mechanism by detecting changes in phosphorylation levels.

What experimental approaches can be used to study the inhibition of ATG36 by the peroxisomal exportomer?

The peroxisomal exportomer (Pex1/6 ATPase complex) directly inhibits phosphoactivation of ATG36 by Hrr25. This inhibition can be studied using several approaches with ATG36 antibodies:

• Comparative phosphorylation analysis: Use immunoblotting with ATG36 antibodies to compare phosphorylation levels in wild-type cells versus cells with mutations in exportomer components (e.g., pex1 mutants or pex6 WB [Walker B] mutants that lack ATPase activity) .

• Protein engineering approaches: Study ATG36 regulation using chimeric protein scaffolds like cytoPex15-cytoPex3 that recruit Pex1/6 to ATG36 in a cytosolic context . ATG36 antibodies can detect changes in phosphorylation status in these engineered systems.

• N-terminal truncation analysis: ATG36 antibodies can be used to study how N-terminal truncations of ATG36 (e.g., ΔN30 atg36) affect phosphorylation levels and pexophagy activation .

• Quantitative proteomics: When combined with mass spectrometry, immunoprecipitation with ATG36 antibodies can reveal how the composition of ATG36-containing complexes changes with mutations in the exportomer, as seen with the finding that ATG36 abundance increased ~2.2-fold in complexes isolated from cells expressing Pex6 WB .

When designing these experiments, it's critical to include appropriate controls, such as ATPase-deficient mutants of Pex1 or Pex6, to confirm that observed effects are due to the ATPase activity of the exportomer.

Can ATG36 function be reconstituted in other autophagy pathways?

One remarkable property of ATG36 is its ability to function as a generic autophagy receptor when redirected to different organelles. Researchers can use ATG36 antibodies to study this adaptability:

ATG36 can restore mitophagy in cells lacking the mitochondrial autophagy receptor Atg32 when it is redirected to mitochondria. This was demonstrated by expressing OM45-Pex3 (a fusion of the mitochondrial protein OM45 with Pex3) in atg32Δ pex3Δ cells, which recruited endogenous ATG36 to mitochondria and restored mitophagy .

To study this phenomenon:

• Use ATG36 antibodies to confirm localization to the non-native organelle

• Monitor the degradation of organelle-specific markers (e.g., OM45-GFP for mitochondria)

• Verify that the reconstituted autophagy is dependent on ATG36 by performing the same experiments in atg36Δ backgrounds

This adaptability highlights the modular nature of selective autophagy receptors and suggests that ATG36's primary function is to link its cargo to the autophagy machinery via interactions with Atg11 and Atg8.

What are the optimal protocols for immunoprecipitation with ATG36 antibodies?

For successful immunoprecipitation of ATG36 and its interacting partners:

• Cell growth conditions: Grow cells in appropriate media to modulate ATG36 expression and phosphorylation:

  • Oleate medium for increased ATG36 expression

  • Starvation medium for enhanced interactions with autophagy components (Atg11, Atg8)

• Cell lysis buffer: Use a buffer that preserves protein-protein interactions while effectively extracting membrane-associated proteins:

  • Include detergents like 0.5-1% NP-40 or Triton X-100

  • Add phosphatase inhibitors to preserve phosphorylation status

  • Include protease inhibitor cocktail to prevent degradation

• Immunoprecipitation approach: Based on the published protocols, protein-A tagged ATG36 (ATG36-PtA) can be immunoprecipitated using IgG sepharose beads, with proteins eluted by TEV protease cleavage . Alternatively, commercial antibodies against native ATG36 can be used with protein A/G beads.

• Controls to include:

  • Negative control: Immunoprecipitation of an unrelated protein (e.g., Mvp1-PtA was used as a control in published studies)

  • Positive control: Include samples from conditions known to enhance the interaction of interest

  • Input control: Always analyze a portion of the initial lysate

How can ATG36 antibodies be optimized for immunofluorescence studies?

When using ATG36 antibodies for immunofluorescence microscopy to study pexophagy:

• Fixation methods:

  • For yeast cells, 4% paraformaldehyde fixation for 30 minutes followed by spheroplasting with zymolyase

  • Ensure permeabilization steps do not disrupt the peroxisomal membrane

• Colocalization studies:

  • Combine ATG36 antibodies with markers for:

    • Peroxisomes (e.g., Pex11-GFP)

    • Pre-autophagosomal structure (e.g., GFP-Atg11)

    • Autophagy machinery (e.g., HA-Atg8)

• Quantification approaches:

  • For studying proximity between peroxisomes and autophagy structures (e.g., Atg11-positive structures), count the percentage of cells showing close proximity or colocalization

  • Use appropriate genetic backgrounds (atg1Δ is useful as it blocks autophagosome formation, allowing visualization of accumulated structures)

Published data show that in atg1Δ cells, >65% of cells show close proximity between GFP-Atg11 puncta and peroxisomes, whereas in atg1Δ atg36Δ cells, this drops to <15% . This quantitative approach can be valuable for studying factors that affect ATG36-dependent recruitment of peroxisomes to the autophagy machinery.

What are common challenges with ATG36 detection and their solutions?

When working with ATG36 antibodies, researchers may encounter several challenges:

• Low signal intensity:

  • ATG36 is expressed at relatively low levels under standard growth conditions

  • Solution: Induce peroxisome proliferation with oleate medium to increase ATG36 expression

  • Alternatively, use epitope-tagged versions (ATG36-GFP, ATG36-PtA) for enhanced detection

• Multiple bands in immunoblots:

  • ATG36 appears as fuzzy bands due to differential phosphorylation

  • Solution: Include phosphatase treatment controls to confirm phosphorylation-dependent mobility shifts

  • Use gradient gels (8-12%) for better resolution of phosphorylated species

• Rapid degradation during pexophagy:

  • ATG36 is degraded along with peroxisomes during pexophagy

  • Solution: Use atg1Δ backgrounds to block autophagy progression or include vacuolar protease inhibitors

  • Monitor the GFP cleavage product in ATG36-GFP expressing cells as a marker of vacuolar entry

• Distinguishing between autophagy-dependent and independent degradation:

  • ATG36 can be degraded via autophagy-independent mechanisms

  • Solution: Compare ATG36 levels in wild-type versus atg1Δ cells and monitor GFP cleavage products

How can researchers validate the specificity of ATG36 antibodies?

To ensure ATG36 antibody specificity:

• Genetic validation:

  • Compare immunoblot or immunofluorescence signals between wild-type and atg36Δ cells

  • Use cells expressing ATG36 at different levels (e.g., endogenous versus overexpressed) to confirm signal correlation with expression

• Epitope competition assays:

  • Pre-incubate antibodies with purified ATG36 protein or peptide before immunodetection

  • Signal should be reduced or eliminated when the specific epitope is blocked

• Cross-reactivity assessment:

  • Test antibodies against related autophagy receptors or in other yeast species

  • Determine if antibodies recognize specific post-translational modifications (e.g., phosphorylated forms)

• Multiple antibody validation:

  • When possible, compare results using antibodies targeting different epitopes of ATG36

  • Confirm key findings with both N-terminal and C-terminal targeted antibodies

How should researchers interpret ATG36 phosphorylation patterns in different experimental conditions?

ATG36 phosphorylation status is a key indicator of its activation, but interpretation requires careful consideration:

• Growth condition effects:

  • In oleate medium: ATG36 levels increase but without inducing pexophagy, showing multiple phosphorylation states

  • In starvation medium: Phosphorylation pattern changes and pexophagy is activated

  • In rich medium: Phosphorylation is inhibited by the Pex1/6 ATPase complex

• Phosphorylation pattern analysis:

  • ATG36 appears as "fuzzy bands" with different mobility depending on growth conditions

  • These bands show differential sensitivity to phosphatase (CIP) treatment

  • Higher phosphorylation correlates with pexophagy activation

• Correlation with pexophagy:

  • Importantly, there is no direct correlation between total ATG36 expression levels and pexophagy

  • An increase in ATG36 levels alone is not sufficient to trigger pexophagy

  • Pexophagy requires both ATG36 presence and its activation via phosphorylation under starvation conditions

When designing experiments to study ATG36 phosphorylation, researchers should include appropriate controls:

• Phosphatase-treated samples

• ATG36 variants with mutations in phosphorylation sites

• Kinase inhibitor treatments or kinase mutants (e.g., Hrr25)

What experimental design is recommended for studying ATG36-dependent pexophagy?

For robust studies of ATG36-dependent pexophagy:

• Sequential media conditions:

  • Grow cells in glucose (repression of peroxisomes)

  • Shift to oleate medium (peroxisome proliferation and ATG36 upregulation)

  • Transfer to starvation medium (induction of pexophagy)

• Pexophagy monitoring methods:

  • Western blot analysis of peroxisomal marker processing (e.g., Pex11-GFP cleavage)

  • Microscopy to visualize peroxisome delivery to the vacuole

  • Biochemical assays for peroxisomal enzyme activities

• Genetic backgrounds to include:

  • Wild-type control

  • atg36Δ (negative control for pexophagy)

  • atg1Δ (blocks autophagosome formation)

  • pex3 mutants that specifically affect ATG36 binding

• Time course analysis:

  • ATG36 expression and phosphorylation changes dynamically

  • Pexophagy typically begins after 2-6 hours in starvation medium

  • ATG36 is degraded along with peroxisomes during pexophagy

The table below summarizes key experimental conditions for studying ATG36-dependent pexophagy:

What are emerging applications of ATG36 antibodies in pexophagy research?

As research on ATG36 and pexophagy advances, several emerging applications for ATG36 antibodies show promise:

• Proximity labeling approaches:

  • Combining ATG36 antibodies with proximity labeling techniques (BioID, APEX) to identify novel interacting partners at the peroxisome-autophagy interface

  • These approaches could help identify additional regulatory components beyond the known Pex3-ATG36-Atg11/8 axis

• Structural studies:

  • Using antibodies for protein purification to facilitate structural determination of ATG36 in complex with its binding partners

  • Understanding how phosphorylation induces conformational changes in ATG36

• Single-molecule studies:

  • Employing fluorescently labeled ATG36 antibodies for super-resolution microscopy to track individual ATG36 molecules during pexophagy

  • Analyzing the dynamics of ATG36 recruitment to the pre-autophagosomal structure

• Reconstitution systems:

  • Developing in vitro reconstitution systems with purified components to dissect the precise mechanisms of ATG36 regulation

  • Using ATG36 antibodies to monitor protein interactions in these reconstituted systems

• Therapeutic applications:

  • Exploring ATG36-related pathways in human cells to identify potential therapeutic targets for peroxisomal disorders

  • Developing tools based on ATG36 mechanisms to modulate pexophagy in disease models

How can researchers apply knowledge about ATG36 to human pexophagy studies?

While ATG36 is specific to yeast, the principles learned from studying this protein can inform research on human pexophagy:

• Identification of functional homologs:

  • Though no direct sequence homolog exists in humans, NBR1 and p62 function as pexophagy receptors in mammalian cells

  • ATG36 antibodies can serve as controls when validating antibodies against these human receptors

• Comparative studies:

  • Parallel analysis of regulation mechanisms in yeast and human systems

  • Investigation of whether the exportomer inhibition mechanism is conserved in human cells

• Reconstitution experiments:

  • Testing whether human pexophagy receptors can functionally replace ATG36 in yeast

  • Using chimeric proteins combining domains from yeast ATG36 and human receptors

• Disease models:

  • Applying lessons from ATG36 regulation to understand dysregulated pexophagy in human peroxisomal disorders

  • Developing tools to monitor pexophagy in patient-derived cells

By leveraging the detailed mechanistic understanding of ATG36 function in yeast, researchers can develop more sophisticated approaches to studying pexophagy in human cells and potentially identify novel therapeutic targets for peroxisomal disorders.